Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 33Dermatologic 16Thoracic 6Genitourinary 4Sarcoma 2Gynecologic 2Gastrointestinal 2Breast 2Head & Neck 1

Conditions

Carcinoma, Hepatocellular 87Colorectal Neoplasms 82Stomach Neoplasms 59Pancreatic Neoplasms 56Carcinoma, Non-Small-Cell Lung 46Melanoma 34Carcinoma, Renal Cell 29Neoplasm Metastasis 25Neoplasms 24Esophageal Neoplasms 24Colonic Neoplasms 22Squamous Cell Carcinoma of Head and Neck 21Carcinoma, Transitional Cell 20Liver Neoplasms 19Ovarian Neoplasms 17Adenocarcinoma Of Esophagus 17Esophageal Squamous Cell Carcinoma 16Triple Negative Breast Neoplasms 15Rectal Neoplasms 15Breast Neoplasms 14Biliary Tract Neoplasms 14Uterine Cervical Neoplasms 13Lung Neoplasms 12Cholangiocarcinoma 12Carcinoma, Merkel Cell 12Head and Neck Neoplasms 10Prostatic Neoplasms 9Gastrointestinal Neoplasms 9Small Cell Lung Carcinoma 8Endometrial Neoplasms 8

Interventions

Magnetic Resonance Spectroscopy 7Radiotherapy 6Radiosurgery 4pembrolizumab 3Specimen Handling 3Paclitaxel 3Fluorodeoxyglucose F18 3Carboplatin 3sargramostim 2cediranib 2Thiotepa 2Radiation 2Nivolumab 2Melphalan 2IFL protocol 2Granulocyte Colony-Stimulating Factor 2Genetic Testing 2Gemcitabine 2FAPI-46 2Busulfan 2130-nm albumin-bound paclitaxel 2tipifarnib 1sodium thiosulfate 1regorafenib 1paclitaxel-Angiopep-2 conjugate 1montelukast 1etoposide phosphate 1entrectinib 1entinostat 1clevudine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Brain Neoplasms × Nivolumab × Gastrointestinal × Clear all
NCT07492680 2026-05-29

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Bristol-Myers Squibb

Phase 2 Not yet recruiting
260 enrolled
CNSDermatologicGastrointestinal

Brain Neoplasms, Melanoma, Pancreatic Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡